Safety is predictable with NERLYNX3
MOST COMMON AEs (≥5%) IN ExteNET3
There was no evidence of cardiac or serious pulmonary toxicity nor increased risk for secondary malignancy observed in ExteNET2,22
AE: adverse event.
IMPORTANT SAFETY INFORMATION
NERLYNX® (neratinib) tablets, for oral use
INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:
To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS:
For Full Prescribing Information, please click here.
By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.
This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.